Supernus Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted seven years of orphan-drug exclusivity for its product ONAPGO (apomorphine HCl). This approval is significant as it allows Supernus to maintain exclusive rights to market ONAPGO for treating motor fluctuations in adults with advanced Parkinson's disease. The exclusivity period began on February 3, 2025, the date of the drug's initial FDA approval.

The announcement, made on October 21, 2026, marks a notable achievement for Supernus, which focuses on developing treatments for central nervous system (CNS) disorders. The company also submitted a supplemental New Drug Application (sNDA) to the FDA for a second supplier of ONAPGO, with expectations of approval by mid-2027.

Background

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company incorporated in Delaware and listed on the Nasdaq under the ticker SUPN. The company specializes in developing and commercializing products aimed at treating CNS diseases. Its recent filings include various 8-K forms, with the latest one dated October 22, 2026.

What the Filing Says

The filing states: "On October 21, 2026, Supernus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease." It further mentions that the company has submitted a supplemental New Drug Application to the FDA for a second supplier for ONAPGO.

Impact

This exclusivity is expected to positively impact Supernus by securing its market position in the CNS treatment sector. The orphan-drug designation not only emphasizes the importance of ONAPGO in treating a specific patient population but also highlights the company's commitment to addressing the needs of patients suffering from Parkinson's disease. Other pharmaceutical companies in the CNS sector will likely monitor Supernus's progress closely.

What's Next

The filing does not say what happens next regarding further developments or additional approvals.